Your browser doesn't support javascript.
loading
Patient-specific molecular alterations are associated with metastatic clear cell renal cell cancer progressing under tyrosine kinase inhibitor therapy.
Dietz, Steffen; Sültmann, Holger; Du, YueJun; Reisinger, Eva; Riediger, Anja Lisa; Volckmar, Anna-Lena; Stenzinger, Albrecht; Schlesner, Matthias; Jäger, Dirk; Hohenfellner, Markus; Duensing, Stefan; Grüllich, Carsten; Pahernik, Sascha.
Afiliação
  • Dietz S; Cancer Genome Research Group, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Sültmann H; Cancer Genome Research Group, German Cancer Consortium (DKTK), Heidelberg, Germany, German Cancer Research Center (DKFZ) and National Center for Tumor Diseases (NCT), Heidelberg, Germany.
  • Du Y; Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
  • Reisinger E; Department of Urology, Nanfang Hospital of Southern Medical University, Guangzhou, China.
  • Riediger AL; Data Management Group, Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), and Heidelberg Center for Personalized Oncology (DKFZ-HIPO), Heidelberg, Germany.
  • Volckmar AL; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Stenzinger A; Institute of Pathology, University Hospital Heidelberg, and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Schlesner M; Institute of Pathology, University Hospital Heidelberg, and German Cancer Consortium (DKTK), Heidelberg, Germany.
  • Jäger D; Division of Theoretical Bioinformatics, German Cancer Research Center (DKFZ), Heidelberg, Germany.
  • Hohenfellner M; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
  • Duensing S; Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
  • Grüllich C; Section of Molecular Urooncology, Department of Urology, Heidelberg University Hospital, Heidelberg, Germany.
  • Pahernik S; Department of Medical Oncology, National Center for Tumor Diseases (NCT), Heidelberg University Hospital, Heidelberg, Germany.
Oncotarget ; 8(43): 74049-74057, 2017 Sep 26.
Article em En | MEDLINE | ID: mdl-29088767
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Tipo de estudo: Risk_factors_studies Idioma: En Revista: Oncotarget Ano de publicação: 2017 Tipo de documento: Article País de afiliação: Alemanha